MA
TEVA icon

Montag & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Montag & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23
Closed -$465 – 1152
2025
Q3 		$465 Buy
+23
New +$404 ﹤0.01% 1087

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Montag & Associates's TEVA Position: Q4 2025 in Review

Montag & Associates sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 23 shares — an estimated $465 sold.

Montag & Associates first reported a position in TEVA in Q3 2025 and held it in 1 quarter. The position peaked at $465 in Q3 2025. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Montag & Associates reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Montag & Associates sold 23 Teva Pharmaceuticals shares in Q4 2025, an estimated $465.
  • Montag & Associates first reported a position in Teva Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Montag & Associates's Teva Pharmaceuticals position peaked at $465 in Q3 2025.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.